Utah Medical Products, Inc.: stock overview
Price
$71.97
November 13, 2026Market cap $229M
What Ploutos Investor adds for Utah Medical Products
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from 2009
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
In short
Utah Medical Products had revenue of $35M over the last 12 months and net income of $11M, a net margin of 30.5%. Revenue fell by 1.8% a year on average over the last 5 years. At $71.97 the shares trade at a P/E of 21.5, against a median of 18.4 over the last 5 fiscal years. It holds more cash than debt, by $85M. It pays a dividend yielding 1.72%.
From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 13, 2026.
Its SEC filings- Market cap
- $229M
- 3.19M shares
- P/E
- 21.5
- Today21.5Median18.4
- Revenue, 12 months
- $35M
- -1.8% a year over 5 years
- Net margin
- 30.5%
- 2025: 29.3%, above 96% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-12.4% a year over 2 years
Fiscal years in figures
UTMD's revenue, profit, cash flow and dividend with each year-end price, from 2009 to 2022, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
- Market cap 3-year median: $202M
- $229M
- Enterprise value
- $144M
- P/E 3-year median: 16.1
- 21.5
- EV / EBIT
- 13.8
- EV / Revenue
- 4.1
- P/B 3-year median: 1.7
- 1.9
- FCF yield 3-year median: 7.2%
- 4.7%
- Earnings yield 3-year median: 6.2%
- 4.6%
Profitability
- Gross margin
- 57.7%
- Operating margin
- 29.9%
- Net margin 3-year median: 33.1%
- 30.5%
- ROIC
- 7.1%
- ROIC, 5-year average
- 10.9%
- ROE
- 8.8%
Growth
- Revenue, yearly change
- -5.8%
- EPS, yearly change
- -12.1%
- FCF, yearly change
- -1.9%
- Revenue, average a year
- -1.8%
- EPS, average a year
- +3.4%
The yearly change compares FY2025 with FY2024.
Balance sheet
- Cash
- $85M
- Total debt
- $180.0K
- Net cash
- $85M
- Net debt / EBITDA
- -7.5x
- Interest cover
- –
- Current ratio
- 21.23
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield 3-year median: 2.0%
- 1.72%
- Buybacks
- 3.64%
- Total returned
- 5.36%
- Shares, yearly change
- -2.9%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
57.1%
Above 50% of the 161 companies in its industry, and 75% of all.
Operating margin
29.6%
Above 99% of the 186 companies in its industry, and 92% of all.
Net margin
29.3%
Above 96% of the 189 companies in its industry, and 90% of all.
ROE
9.5%
Above 68% of the 174 companies in its industry, and 58% of all.
ROA
9.2%
Above 81% of the 190 companies in its industry, and 86% of all.
Revenue growth
-5.8%
Above 13% of the 186 companies in its industry, and 15% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- UTAH MEDICAL PRODUCTS INC
- CIK
- 706698
- Exchange
- NASDAQ
- Industry (SIC)
- 3841 · Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- December 31
- Latest annual report
- December 31, 2025
- Reporting currency
- USD
- Shares
- 3.19M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with UTMD
- JNJJohnson & Johnson+0,00%Compare with UTMD
- ABBVAbbVie+0,00%Compare with UTMD
- UNHUnitedHealth+0,00%Compare with UTMD
- MRKMerck & Company+0,00%Compare with UTMD
- AMGNAmgen+0,00%Compare with UTMD
- TMOThermo Fisher Scientific+0,00%Compare with UTMD
- ABTAbbott Laboratories+0,00%Compare with UTMD
The full analysis
What do Utah Medical Products's filings show?
These are Utah Medical Products's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
What is UTMD's market cap?
Utah Medical Products, Inc.'s market cap is $229M, at a price of $71.97 on November 13, 2026 and 3.19M shares.
What is UTMD's P/E?
UTMD's P/E is 21.5, on earnings per share of $3.34 over the last 12 months. The median over the last 5 fiscal years was 18.4.
How much revenue does UTMD have?
Utah Medical Products had revenue of $35M over the last 12 months. Over the last 5 years it changed by -1.8% a year on average.
Does UTMD pay a dividend?
Yes. Utah Medical Products paid $1.24 per share over the last 12 months, a yield of 1.72% at today's price. All the figures are in the Dividend section.
Where do the figures come from?
From Utah Medical Products, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.